Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1189-1196

  Nara, Keigo ^a   Kusafuka, Takeshi ^b   Yoneda, Akihiro ^a   Oue, Takaharu ^a   Sangkhathat, Surasak ^a   Fukuzawa, Masahiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

MYCN; Neuroblastoma; RNA interference

Indexed keywords

COMPLEMENTARY DNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; GENOME; HUMAN; METABOLISM; NEUROBLASTOMA; NICK END LABELING; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, COMPLEMENTARY; GENE SILENCING; GENOME, HUMAN; HUMANS; IN SITU NICK-END LABELING; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34447324976     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1189     Document Type: Article

References (40)

1. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK and Robison LL: Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 19: 428-432, 1997.
2. Matthay KK: Neuroblastoma: a clinical challenge and biologic puzzle. CA: Cancer J Clin 45: 179-192, 1995.
3. Young JL Jr and Miller RW: Incidence of malignant tumors in U.S. children. J Pediatr 86: 254-258, 1975.
4. Kawa K, Ohnuma N, Kaneko M, et al: Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 17: 3216-3220, 1999.
5. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173, 1999.
6. Lu X, Pearson A and Lunec J: The MYCN oncoprotein as a drug development target. Cancer Lett 197: 125-130, 2003.
7. Westermann F and Schwab M: Genetic parameters of neuroblastomas. Cancer Lett 184: 127-147, 2002.
8. Schwab M, Varmus HE, Bishop JM, et al: Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308: 288-291, 1984.
9. Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124, 1984.
10. Nakagawara A and Ikeda K: N-myc oncogene amplification and catecholamine metabolism in children with neuroblastoma. Lancet i: 559, 1987. (Pubitemid 17020750)
11. Nisen PD, Waber PG, Rich MA, et al: N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 80: 1633-1637, 1988.
12. Bordow SB, Norris MD, Haber PS, Marshall GM and Haber M: Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 16: 3286-3294, 1998.
13. Slavc I, Ellenbogen R, Jung WH, et al: myc gene amplification and expression in primary human neuroblastoma. Cancer Res 50: 1459-1463, 1990.
14. Cohn SL, London WB, Huang D, et al: MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 18: 3604-3613, 2000.
15. Matthay KK: MYCN expression in neuroblastoma: a mixed message? J Clin Oncol 18: 3591-3594, 2000.
16. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995, 1997.
17. Manohar CF, Bray JA, Salwen HR, et al: MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23: 753-762, 2004.
18. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998.
19. Scherr M, Morgan MA and Eder M: Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem 10: 245-256, 2003.
20. Dorsett Y and Tuschl T: siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3: 318-329, 2004.
21. Ovcharenko D, Jarvis R, Hunicke-Smith S, Kelnar K and Brown D: High-throughput RNAi screening in vitro: from cell lines to primary cells. RNA 11: 985-993, 2005.
22. Tanaka S, Tajiri T, Noguchi S, et al: Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. J Pediatr Surg 39: 63-68, 2004.
23. Ohno S, Nishi T, Kojima Y, Haraoka J, Ito H and Mizuguchi J: Combined stimulation with interferon alpha and retinoic acid synergistically inhibits proliferation of the glioblastoma cell line GB12. Neurol Res 24: 697-704, 2002.
24. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19: 1518-1520, 1996.
25. Tonelli R, Purgato S, Camerin C, et al: Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 4: 779-786, 2005.
26. Fan S, Ramirez SH, Garcia TM and Dewhurst S: Dishevelled promotes neurite outgrowth in neuronal differentiating neuroblastoma 2A cells, via a DIX-domain dependent pathway. Brain Res 132: 38-50, 2004.
27. Tijsterman M and Plasterk RH: Dicers at RISC; the mechanism of RNAi. Cell 117: 1-3, 2004.
28. Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A and Raschella G: Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 2: 511-518, 1991.
29. Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM and Cotter FE: In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. Int J Cancer 98: 128-133, 2002.
30. Schmidt ML, Lal A and Dittmann D: Differential expression in an antisense MYCN neuroblastoma model. Med Pediatr Oncol 35: 669-672, 2000.
31. Miyagishi M, Hayashi M and Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 13: 1-7, 2003.
32. Biewenga JE, Destree OH and Schrama LH: Plasmid-mediated gene transfer in neurons using the biolistics technique. J Neurosci Methods 71: 67-75, 1997.
33. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev 3: 203-216, 2003.
34. Peaston AE, Gardaneh M, Franco AV, et al: MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 85: 1564-1571, 2001.
35. Galderisi U, Di Bernardo G, Melone MA, et al: Antisense inhibitory effect: a comparison between 3′-partial and full phosphorothioate antisense oligonucleotides. J Cell Biochem 74: 31-37, 1999.
36. Schmidt ML, Salwen HR, Manohar CF, Ikegaki N and Cohn SL: The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 5: 171-178, 1994.
37. Nakagawara A, Arima M, Azar CG, Scavarda NJ and Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368, 1992.
38. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB and Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847-854, 1993.
39. Brodeur GM, Nakagawara A, Yamashiro DJ, et al: Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31: 49-55, 1997. (Pubitemid 27077709)
40. Tanaka T, Sugimoto T and Sawada T: Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. Cancer 83: 1626-1633, 1998.